Compare · ARGX vs SLDB
ARGX vs SLDB
Side-by-side comparison of argenx SE (ARGX) and Solid Biosciences Inc. (SLDB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and SLDB operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $63.27B, about 59.7x SLDB ($1.06B).
- Over the past year, ARGX is up 44.0% and SLDB is up 73.1% - SLDB leads by 29.1 points.
- ARGX has been more active in the news (11 items in the past 4 weeks vs 8 for SLDB).
- ARGX has more recent analyst coverage (25 ratings vs 16 for SLDB).
- Company
- argenx SE
- Solid Biosciences Inc.
- Price
- $1019.71+0.82%
- $9.90+7.96%
- Market cap
- $63.27B
- $1.06B
- 1M return
- +14.62%
- +25.63%
- 1Y return
- +43.97%
- +73.08%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2018
- News (4w)
- 11
- 8
- Recent ratings
- 25
- 16
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Solid Biosciences Inc.
Solid Biosciences Inc., a life science company, engages in developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles. Its portfolio also comprises Anti-LTBP4, a complementary disease modifying program that identifies and develops a monoclonal antibody intended to reduce fibrosis and inflammation by targeting and stabilizing the LTBP4 protein. In addition, the company engages in developing biomarkers and sensors; and Solid Suit program that includes the development of wearable assistive devices that focus on providing functional and therapeutic benefits. Solid Biosciences Inc. has strategic collaboration with Ultragenyx to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Latest ARGX
- argenx downgraded by Deutsche Bank
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- SEC Form 6-K filed by argenx SE
- Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
- argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.
- SEC Form SC TO-T filed by argenx SE
- Guggenheim resumed coverage on argenx with a new price target
- SEC Form 6-K filed by argenx SE
Latest SLDB
- Truist resumed coverage on Solid Biosciences with a new price target
- Amendment: SEC Form SCHEDULE 13D/A filed by Solid Biosciences Inc.
- SEC Form 8-K filed by Solid Biosciences Inc.
- SEC Form 424B5 filed by Solid Biosciences Inc.
- SEC Form S-3ASR filed by Solid Biosciences Inc.
- Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates
- SEC Form 10-Q filed by Solid Biosciences Inc.
- SEC Form SCHEDULE 13G filed by Solid Biosciences Inc.
- Director Smith Ian F converted options into 3,440 shares, increasing direct ownership by 3% to 138,145 units (SEC Form 4)
- New insider Ra Capital Management, L.P. claimed ownership of 12,036,126 shares (SEC Form 3)